Genetic susceptibility testing and prophylactic oophorectomy

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 82, Issue 2, 1999, Pages 159-164

  Berchuck, Andrew ^a   Carney, Michael E ^a   Futreal, P Andrew ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

BRCA1; BRCA2; Oophorectomy; Ovarian cancer

Indexed keywords

BREAST CANCER; CANCER GENETICS; CANCER SUSCEPTIBILITY; CONFERENCE PAPER; FAMILIAL CANCER; FEMALE; GENE MUTATION; HUMAN; OVARIECTOMY; OVARY CANCER; PRIORITY JOURNAL;

EID: 0033012107     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(98)00220-6     Document Type: Conference Paper

References (42)

1. Piver M.S., Baker T.R., Jishi M.F.et al. Familial ovarian cancer. A report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981-1991. Cancer. 71:1993;582-588.
2. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
3. Boyd M., Harris F., McFarlane R., Davidson H.R., Black D.M. A human BRCA1 gene knockout. Nature. 375:1995;541-542.
4. Smith S.A., Easton D.F., Evans D.G., Ponder B.A. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet. 2:1992;128-131.
5. Scully R., Chen J., Plug A.et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell. 88:1997;265-275.
6. Ford D., Easton D.F. The genetics of breast and ovarian cancer. Br J Cancer. 72:1995;805-812.
7. Easton D.F., Ford D., Bishop D.T. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 56:1995;265-271.
8. Ford D., Easton D.F., Bishop D.T., Narod S.A., Goldgar D.E. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 343:1994;692-695.
9. Rebbeck T.R., Couch F.J., Calzone K.et al. Genetic heterogeneity in hereditary breast cancer: Role of BRCA1 and BRCA2. Am J Hum Genet. 59:1996;547-553.
10. Serova O.M., Mazoyer S., Puget N.et al. Mutations in BRCA1 and BRCA2 in breast cancer families: Are there more breast cancer-susceptiility genes? Am J Hum Genet. 60:1997;486-495.
11. Couch F.J., DeShand M.L., Blackwood A.et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. New Engl J Med. 336:1997;1409-1415.
12. Langston A.A., Malone K.E., Thompson J.D., Daling J.R., Ostrander E.A. BRCA1 mutations in a population-based sample of young women with breast cancer. New EngI J Med. 334:1996;137-142.
13. Whittemore A.S., Gong G., Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet. 60:1997;496-504.
14. Struewing J.P., Hartge P., Wacholder S.et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. New Engl J Med. 336:1997;1401-1408.
15. Gayther S.A., Warren W., Mazoyer S.et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for genotype-phenotype correlation. Nat Genet. 11:1995;428-433.
16. Shattuck-Eidens D., Oliphant A., McClure M.et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. J Am Med Assoc. 278:1997;1242-1250.
17. Phelan C.M., Rebbeck T.R., Weber B.L.et al. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet. 12:1996;309-311.
18. Narod S., Goldgar D., Cannon-Albright L.et al. Risk modifiers in carriers of BRCA1 mutations. Int J Cancer. 64:1995;394-398.
19. Wooster R., Bignell G., Lancaster J.et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 378:1995;789-791.
20. Phelan C.M., Lancaster J.M., Cumbs C.et al. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet. 13:1996;120-122.
21. Lancaster J.M., Wooster R., Mangion J.et al. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet. 13:1996;1-5.
22. Gayther S.A., Mangion J., Russell P.et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet. 15:1997;103-105.
23. Ford D., Easton D.F., Stratton M.et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 62:1998;676-689.
24. Couch F.J., Weber B.L. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Hum Mutation. 8:1996;8-18.
25. Shattuck-Eidens D., McClure M., Simard J.et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. J Am Med Assoc. 273:1995;535-541.
26. Szabo C.L., King M.C. Invited editorial: Population genetics of BRCA1 and BRCA2. Am J Hum Genet. 60:1997;1013-1020.
27. Peelen T, Cornelis RS, van VM, et al. The majority of 22 Dutch high-risk breast cancer families are due to either BRCA1 or BRCA2. Eur J Hum Genet 1996;4:225-230.
28. Petrij-Bosch A, Peelen T, van VM, et al. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 1997;17:341-345.
29. Kerlikowske K., Brown J.S., Grady D.G. Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol. 80:1992;700-707.
30. Lynch H.T., Albano W.A., Lynch J.F., Lynch P.M., Campbell A. Surveillance and management of patients at high genetic risk for ovarian carcinoma. Obstet Gynecol. 59:1982;589-596.
31. Lynch H.T., Lemon S.J., Durham C.et al. A descriptive study of BRCA1 testing and reactions to disclosure of test results. Cancer. 79:1997;2219-2228.
32. Lynch H.T., Lemon S.J., Karr B.et al. Etiology, natural history, management and molecular genetics of hereditary nonpolyposis colorectal cancer (Lynch syndromes): genetic counseling implications. Cancer Epidemiol Biomarkers Prey. 6:1997;987-991.
33. Gusberg S.B., Deligdisch L. Ovarian dysplasia. A study of identical twins. Cancer. 54:1984;1-4.
34. Salazar H., Godwin A.K., Daly M.B.et al. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst. 88:1996;1810-1820.
35. Plaxe S.C., Deligdisch L., Dottino P.R., Cohen C.J. Ovarian intraepithelial neoplasia demonstrated in patients with stage I ovarian carcinoma. Gynecol Oncol. 38:1990;367-372.
36. Resta L., Russo S., Colucci G.A., Prat J. Morphologic precursors of ovarian epithelial tumors. Obstet Gynecol. 82:1993;181-186.
37. Tobacman J.K., Greene M.H., Tucker M.A., Costa J., Kase R., Fraumeni J.F. Jr. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer prone families. Lancet. 2:1982;795-797.
38. Piver M.S., Jishi M.F., Tsukada Y., Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer. 71:1993;2751-2755.
39. Struewing JP, Watson P, Easton DF, Ponder BA, Lynch HT, Tucker MA. Prophylactic oophorectomy in inherited breast/ovarian cancer families. Monogr Natl Cancer Inst 1995;33-35.
40. Weber A.M., Hewett W.J., Gajewski W.H., Curry S.L. Serous carcinoma of the peritoneum after oophorectomy. Obstet Gynecol. 80:1992;558-560.
41. Chen K.T., Schooley J.L., Flam M.S. Peritoneal carcinomatosis after prophylactic oophorectomy in familial ovarian cancer syndrome. Obstet Gynecol. 66:1985;935-945.
42. Menczer J., Ben-Baruch G. Familial ovarian cancer in Israeli Jewish women. Obstet Gynecol. 77:1991;276-277.